Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Geron reported a quarterly loss of $0.04 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.02, representing an earnings surprise of -100% [1] - The company posted revenues of $47.54 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 4.67$0.02 million in the same quarter last year [2] - Over the last four quarters, Geron has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Movement and Outlook - Geron shares have declined approximately 33.1% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.04 on revenues of$57.3 million, and -$0.07 on revenues of$297.85 million for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Geron belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Geron's stock performance [5]